Join the SmallCapReview mailing list





Stereotaxis (Nasdaq: STXS)

A healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. 

With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information.

Stereotaxis' core technologies are the Niobe ES Remote Magnetic Navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems and the Vdrive Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The V-Sono ICE catheter manipulator has received U.S. clearance, and the V-Loop circular catheter manipulator is currently in clinical trials in order to obtain clearance by the U.S. Food and Drug Administration.

More on STXS

Transition Therapeutics (Nasdaq: TTHI)

A biopharmaceutical company that engages in developing therapeutics for various disease indications primarily in Canada. Its product candidates include ELND005 (AZD-103), a Phase II clinical trial product for the treatment of Alzheimers disease and neuropsychiatric disorders; TT-301 and TT-302, which are in Phase I clinical trial for the treatment of rheumatoid arthritis, Alzheimers disease, intracerebral hemorrhage, and traumatic brain injury; and TT401/402, a Phase I clinical trial product to treat diabetes. 

The company also has a pipeline of preclinical and clinical drug candidates for the treatment of anti-inflammatory and metabolic indications. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005 (AZD-103); and Eli Lilly and Company.

More on TTHI

Omeros Corp. (Nasdaq: OMER)

A clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. 

The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. 

Omeros has five clinical development programs.

More on OMER